The Conversation (0)
- AustraliaNorth AmericaWorld
Investing News NetworkYour trusted source for investing success
Top Stocks
Top Resource Stocks
Top Tech Stocks
Top Life Science Stocks
Trending
Trending Articles
Trending Press Releases
Trending Companies
Trending Reports
Resource
Popular Lists
Investing Ideas
Outlook Reports
- Lithium Outlook
- Oil and Gas Outlook
- Gold Outlook Report
- Uranium Outlook
- Rare Earths Outlook
- All Outlook Reports
Investing Guides
Tech
Popular Lists
- Top Generative AI Stocks
- Top EV Stocks
- Biggest AI Companies
- Biggest Blockchain Stocks
- Biggest Cryptocurrency-mining Stocks
- Biggest Cybersecurity Companies
- Biggest Robotics Companies
- Biggest Social Media Companies
- Biggest Technology ETFs
- Artificial Intellgience ETFs
- Robotics ETFs
- Canadian Cryptocurrency ETFs
Investing Ideas
Outlook Reports
- Artificial Intelligence Outlook
- EV Outlook
- Cleantech Outlook
- Crypto Outlook
- Tech Outlook
- All Market Outlook Reports
Investing Guides
Life Science
Popular Lists
- Cannabis Weekly Round-Up
- Top Alzheimer's Treatment Stocks
- Top Biotech Stocks
- Top Plant-based Food Stocks
- Biggest Cannabis Stocks
- Biggest Pharma Stocks
- Longevity Stocks to Watch
- Psychedelics Stocks to Watch
- Top Cobalt Stocks
- Small Biotech ETFs to Watch
- Top Life Science ETFs
- Biggest Pharmaceutical ETFs
Outlook Reports
- Life Science Outlook
- Biotech Outlook
- Cannabis Outlook
- Pharma Outlook
- Psychedelics Outlook
- All Market Outlook Reports
Investing Guides
Precipio Announces Q4 2017 Revenue at 350% of Previous Quarter
Feb. 09, 2018 09:31AM PST
Medical Device InvestingSpecialty diagnostics company Precipio (NASDAQ:PRPO), announces preliminary, unaudited revenues for the 4th quarter of 2017 of approximately $945,000, representing three-fold from the previous quarter of approximately $270,000, as well as a three-fold year-over-year from the 4th quarter of 2016 revenues of approximately $316,000. As quoted in the press release: “Now that assets have been integrated and systems …
Specialty diagnostics company Precipio (NASDAQ:PRPO), announces preliminary, unaudited revenues for the 4th quarter of 2017 of approximately $945,000, representing three-fold from the previous quarter of approximately $270,000, as well as a three-fold year-over-year from the 4th quarter of 2016 revenues of approximately $316,000.
As quoted in the press release:
“Now that assets have been integrated and systems optimized, we have resumed our focus on sales growth and aggressively capturing market share with our disruptive diagnostic products and services,” commented Ilan Danieli, CEO. “Our team worked around the clock to ensure resumption of services within Q3-2017, and our sales growth in Q4 reflects that hard work. We will remain completely focused on continuing this revenue growth throughout the year.”
Latest News
Investing News Network websites or approved third-party tools use cookies. Please refer to the cookie policy for collected data, privacy and GDPR compliance. By continuing to browse the site, you agree to our use of cookies.